Description
Key facts
Detection method:Fluorescent,
Sample types:Saliva, Urine, Tissue Extracts, Heparin Plasma, Citrate plasma, Cell culture supernatant, Serum, EDTA Plasma,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 10.8 pg/mL,
Range:39.1 - 160000 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)
Product details:
Apolipoprotein A-IV
in vitro
CatchPoint
SimpleStep ELISA
(Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of Apolipoprotein A-IV protein in human serum, plasma, saliva, urine, cell culture supernatants, and tissue extract samples.
This CatchPoint SimpleStep ELISA kit has been
optimized for Molecular Devices Microplate Readers
. Click
for a list of recommended Microplate Readers.
If using a Molecular Devices' plate reader supported by SoftMax® Pro software, a preconfigured protocol for these CatchPoint SimpleStep ELISA Kits is available with all the protocol and analysis settings at
www.softmaxpro.org
The CatchPoint
SimpleStep ELISA
employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. CatchPoint
HRP Development Solution containing the Stoplight Red Substrate is added. During incubation, the substrate is catalyzed by HRP generating a fluorescent product. Signal is generated proportionally to the amount of bound analyte and the intensity is measured in a fluorescence plater reader at 530/570/590 nm Excitation/Cutoff/Emission.
Human Apolipoprotein A-IV is a 45kDa glycoprotein with activities involving lipid transport. Specifically, Apolipoprotein A-IV is a component of high density lipoprotein (HDL) and chylomicrons. Its primarily synthesized is the intestine in association with lymph chylomicron particles. Although its precise function is not known, Apolipoprotein A-IV is a potent activator of lecithin-cholesterol acyltransferase (LCAT) in vitro. Human Apolipoprotein A-IV consists of a 20 amino acid (aa) signal peptide and 376 aa mature chain. Human Apolipoprotein A-IV is 62% identical to both mouse and rat Apolipoprotein A-IV.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
APOA4 also known as Apo-AIV or apolipoprotein A4 is a protein mainly expressed in the small intestine and liver. It has a molecular mass of approximately 46 kDa. This protein plays a significant role in lipid metabolism by facilitating the transport of lipids in the bloodstream. APOA4 exists in the plasma and associates predominately with high-density lipoproteins (HDL) and to a lesser extent with chylomicrons.
Biological function summary
Apolipoprotein A4 acts as an important player in the regulation of lipid homeostasis and satiety. This protein is not part of a complex but enhances the efficiency of lipid absorption and transport. APOA4 reacts with enzymes like lecithin-cholesterol acyltransferase which is essential in the maturation of HDL particles. This interaction supports cholesterol efflux and assists in maintaining cholesterol balance within the body.
Pathways
APOA4 is heavily involved in the reverse cholesterol transport pathway which is important for removing excess cholesterol from cells and tissues taking it back to the liver for excretion. Within this pathway APOA4 interacts with key proteins like apolipoprotein A1 and lecithin-cholesterol acyltransferase to aid in this lipid transport mechanism. It also participates in a related lipid homeostasis pathway enhancing lipid absorption efficiency.
Research links APOA4 to atherosclerosis and obesity. Altered expression or function of apolipoprotein A4 often correlates with increased cardiovascular disease risk due to its role in cholesterol transport. It is associated with apolipoprotein A1 as both of these proteins significantly impact lipid profiles related to cardiovascular health. The ability of APOA4 to influence satiety also connects it to obesity suggesting a role in energy balance regulation.
